Your browser doesn't support javascript.
loading
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Chan, John K; Tian, Chunqiao; Kesterson, Joshua P; Richardson, Michael T; Lin, Ken; Tewari, Krishnansu S; Herzog, Thomas; Kapp, Daniel S; Monk, Bradley J; Casablanca, Yovanni; Hanjani, Parviz; Wenham, Robert M; Walker, Joan; McNally, Leah; Copeland, Larry J; Robertson, Sharon; Lentz, Samuel; Spirtos, Nick M; Bell, Jeffery G.
  • Chan JK; Division of Gynecologic Oncology, California Pacific Medical Center, Palo Alto Medical Foundation Research Institute, Palo Alto, CA, United States of America. Electronic address: chanjohn@sutterhealth.org.
  • Tian C; Division of Gynecologic Oncology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Kesterson JP; Division of Gynecologic Oncology, Penn State Health Milton Hershey Medical Center, Hershey, United States of America.
  • Richardson MT; Division of Gynecologic Oncology, University of California, Los Angeles, Los Angeles, CA, United States of America.
  • Lin K; Division of Gynecologic Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, United States of America.
  • Tewari KS; Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, United States of America.
  • Herzog T; Division of Gynecologic Oncology, University of Cincinnati Cancer Institute, Cincinnati, OH, United States of America.
  • Kapp DS; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States of America.
  • Monk BJ; Division of Gynecologic Oncology, Arizona Oncology, University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, AZ, United States of America.
  • Casablanca Y; Division of Gynecologic Oncology, Walter Reed National Military Medical Center, MD, United States of America.
  • Hanjani P; Division of Gynecologic Oncology, Abington Memorial Hospital- Asplundh Cancer Pavilion, Abington, PA, United States of America.
  • Wenham RM; Division of Gynecologic Oncology, Moffitt Cancer Center Institute and Research Institute, Tampa, FL, United States of America.
  • Walker J; Division of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America.
  • McNally L; Division of Gynecologic Oncology, Duke University Medical Center. Durham, NC, United States of America.
  • Copeland LJ; Division of Gynecologic Oncology, Ohio State University Comprehensive Cancer Center, OH, United States of America.
  • Robertson S; Division of Gynecologic Oncology, Indiana University Hospital/Melvin and Bren Simon Cancer Center, IN, United States of America.
  • Lentz S; Division of Gynecologic Oncology, Wake Forest University Health Sciences, NC, United States of America.
  • Spirtos NM; Division of Gynecologic Oncology, Women's Cancer Center of Nevada, LV, United States of America.
  • Bell JG; Division of Gynecologic Oncology, Ohio Riverside Methodist Hospital, Columbus, OH, United States of America.
Gynecol Oncol ; 167(3): 429-435, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36244828
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2022 Tipo del documento: Article